Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Blood group Rh(D) antigen is a complex, multi-pass transmembrane protein expressed exclusively on the surface of erythrocytes (UniProt: P18577). As the most immunogenic antigen within the Rhesus blood group system, it is a primary driver of alloimmunization during pregnancy and blood transfusions (StatPearls: Rh Blood Group System). While its exact physiological role is still being elucidated, it is believed to maintain red blood cell membrane structural integrity and participate in the transport of ammonium ions (NCBI Gene: 6000). In clinical practice, RhD is the target of Rho(D) immune globulin, which is administered to Rh-negative individuals to prevent the formation of anti-D antibodies, thereby avoiding hemolytic disease of the fetus and newborn (HDFN) (PubMed: 29262354). Additionally, it serves as a therapeutic target in immune thrombocytopenic purpura (ITP), where anti-D antibodies are used to induce a controlled hemolysis that saturates splenic Fc receptors, sparing the patient's platelets from destruction (StatPearls: Immune Thrombocytopenic Purpura). The protein's absence or alteration defines the Rh-negative phenotype, which is found in approximately 15% of the Caucasian population (Wikipedia: Rh blood group system). Management of RhD-related conditions remains a cornerstone of modern obstetric care and transfusion safety protocols.
Passive immunization to prevent maternal sensitization to fetal RhD-positive red blood cells; in ITP, it causes competitive inhibition of Fc receptors on splenic macrophages by coating RhD-positive erythrocytes (StatPearls: Rh Blood Group System).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Blood group Rh(D) antigen (RhD).